Sera Prognostics

Sera Prognostics, also known as "The Pregnancy Company", has been a pioneer in the biotechnology and healthcare industries since its inception in 2008. This innovative proteomic and bioinformatics firm is dedicated to empowering healthcare professionals and improving the well-being of expectant mothers and infants through precision biomarker-based tests. The company's flagship product, the PreTRM® Test, provides physicians with individualized risk assessments for premature birth, enabling proactive interventions to mitigate potential complications. Notably, in the latest funding round on 28 April 2021, Sera Prognostics secured a significant $100.00M Series E investment from a consortium of prominent investors, including Vivo Capital, aMoon, Blue Ox Healthcare Partners, Parian Global Management, and Elevance Health. This substantial backing reflects the confidence of leading venture capital firms in the company's vision and potential impact on the global healthcare landscape. With a focus on addressing various pregnancy-related complications such as preeclampsia, gestational diabetes, and growth restriction, Sera Prognostics is poised to amplify its influence and continue shaping the future of prenatal care. For those interested in being part of this transformative journey, Sera Prognostics invites individuals to explore its values, culture, and career opportunities on its website.